Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to improve the diagnosis of cancer and other diseases.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

LabGenomics USA, a subsidiary of South Korean-based diagnostics firm LabGenomics, said Tuesday that it has acquired QDx Pathology for an undisclosed amount.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

Agilent Technologies Inc. announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities.

Leica Biosystems and Paige announced that they are expanding their previously announced digital pathology partnership. ​

Agilent Technologies announced a multiyear distribution agreement with Proscia to offer a comprehensive digital diagnostic pathology system.